Last reviewed · How we verify
NCT05341388
The Effect of SGLT2 Inhibitors on Cognitive Functions and BDNF Levels in Patients With Type 2 Diabetes
trial testing MOCA cognitive evaluation test in Type2 Diabetes in 25 participants. Terminated before completion.
30 November 2021
Quick facts
| Lead sponsor | Goztepe Training and Research Hospital |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 25 |
| Start date | 1 March 2021 |
| Primary completion | 30 November 2021 |
| Estimated completion | 30 November 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- MOCA cognitive evaluation test
- BDNF levels
- SF-36 test
- Geriatric depression test
Conditions studied
- Type2 Diabetes — all drugs for Type2 Diabetes →
- Cognitive Impairment — all drugs for Cognitive Impairment →
Sponsor
Goztepe Training and Research Hospital
Who can join
Adults 60 to 80, any sex, with Type2 Diabetes or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cognitive impairment is a common complication in diabetes for various reasons. Although glycemic control improves cognitive impairment, different antidiabetic medications' effects on cognitive functions are still being investigated. Brain-derived neurotrophic factor (BDNF) is a neuroinflammatory marker and a member of the neurotrophin family with growth factor properties. BDNF levels have been shown to decrease in mild cognitive dysfunction or in late-onset Alzheimer's disease. Our aim is to examine the effect of SGLT2 inhibitor use on cognitive functions and BDNF levels.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05341388
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type2 Diabetes
Currently open trials in the same condition.
- NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
- NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
- NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
- NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
- NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting
Other Goztepe Training and Research Hospital trials
Trials by the same sponsor.
- NCT07302061 — "Effects of Fluid Status and Regional Cerebral Oxygenation on Postoperative Cognitive Dysfunction in Patients Undergoing · active not recruiting
- NCT05394571 — Conditions Associated With Poorly Controlled Diabetes in Patients With Type 2 Diabetes and HbA1c Changes With Therapy · completed
- NCT05188391 — A New Method for Deltoid Ruptures: Gap Sign · NA · unknown
- NCT05062616 — Patient Satisfaction After Ingrown Toenail Surgery · completed
- NCT05164523 — The Effect of SGLT2 Inhibitors on Heart Rate Variability and BDNF Levels in Patients With Type 2 Diabetes · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05341388 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Goztepe Training and Research Hospital
- Last refreshed: 22 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05341388.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing